Stellenwert der Schaumsklerosierung in der Dermatologie

Zusammenfassung

Die Schaumsklerosierung hat als Therapieoption von Varizen unterschiedlichster Ausprägung ihren festen Platz. In der Dermatologie spielt sie in der Behandlung von Patienten mit venösen Ulzera eine wichtige Rolle. Aber auch im operativen Bereich hat sie sich im Management von Seromen und sezernierenden Lymphfisteln als effektiv und sicher erwiesen. Eine bestehende Antikoagulation hat keinen hemmenden Einfluss auf die Effizienz der Schaumsklerosierung.

Abstract

Foam sclerotherapy is well established as efficient and save treatment option in varicose veins. Especially in dermatological patients suffering from venous leg ulcers foam sclerotherapy can be used as causal therapy to improve venous hemodynamics which are relevant for the heeling process. For the management of seromas or the closure of lymph fistulas sclerosant foam is efficient and save.

• Literatur

• 1 Rabe E, Gerlach H, Breu FX et al. Sklerosierungsbehandlung der Varikose. AWMF-Register Nr. 037/015 Stand 05/2012.
• 2 Kreussler. Fachinformationen Aethoxysklerol 0,25 %/0,5 %/1 %/2 %/3 %. Stand Oktober 2009. Wiesbaden: Chemische Fabrik Kreussler & Co GmbH.
• 3 Hamel-Desnos C, Desnos P, Wollmann JC et al. Evaluation of the efficacy of Polidocanol in the form of foam compared with liquid form in sclerotherapy of the long saphenous vein: Initial results. Dermatol Surg 2003; 29: 1170-1175
• 4 Hamel-Desnos C, Ouvry P, Benigni JP et al. Comparison of 1 % and 3 % Polidocanol Foam in Ultrasound Guided Sclerotherapy of the Great Saphenous Vein: A Randomised, Double-Blind Trial with 2 Year-Follow-up. “The 3/1 Study”. Eur J Vasc Endovasc Surg 2007; 34: 723-729
• 5 Rabe E, Otto J, Schliephake D et al. Efficacy and Safety of Great Saphenous Vein Sclerotherapy Using Standardised Polidocanol Foam (ESAF): A Randomised Controlled Multicentre Clinical Trial. Eur J Endovasc Vasc Surg 2008; 35: 238-245
• 6 Alos J, Carreno P, Lopez JA et al. Efficacy and safety of sclerotherapy using Polidocanol foam: A controlled clinical trial. Eur Vasc Endovasc Surg 2006; 31: 101-107
• 7 Ceulen RPM, Bullens Goessens YIJM, Pi-Van de Venne SJA. Outcome and side effectsof duplex-guided sclerotherapy in the treatment of great saphenous vein with1 % versus 3 % polidocanol foam: Results of a randomized controlled trial with 1-year follow up. Dermatol Surg 2007; 33: 276-281
• 8 Myers KA, Jolley D. Factors affecting the risk of deep venous occlusion after ultrasound-guided sclerotherapy for varicose veins. Eur J Vasc Endovasc Surg 2008; 36: 602-605
• 9 Rabe E, Breu F, Cavezzi A et al. European guidelines for sclerotherapy in chronic venous disorders. Phlebology 2013; 29: 338-354
• 10 Kahle B. Stellenwert der Schaumsklerosierung in der Behandlung des Ulcus cruris venosum. Phlebologie 2010; 39: 152-155
• 11 Stücker M, Reich S, Hermes N et al. Safety and efficacy of perilesional sclerotherapy in leg ulcer patients with postthrombotic syndrome and/or oral anticoagulation with phenprocoumon. J Dtsch Dermatol Ges 2006; 4: 734-738
• 12 Obermayer A, Goestl K, Partsch H et al. Venous reflux surgery promotes venous leg ulcer healing despite reduced ankel brachial index. Int Angiol 2008; 27: 239-246
• 13 Obermayer A, Garzon K. Identifying the source of superficial reflux in venous leg ulcers using duplex ultrasound. J Vasc Surg 2010; 52: 1255-1261
• 14 Cabrera J, Redondo P, Becerra A et al. Ultrasound-guided injection of Polidocanol microfoam in the management of venous leg ulcers. Arch Dermatol 2004; 140: 667-673
• 15 Bergan JJ, Pascasrella L, Mekenas LV. Venous disorders: Treatment with sclerosant foam. J Cardiovasc Surg 2006; 47: 9-18
• 16 Pascarella L, Bergan JJ, Mekenas LV. Severe chronic venous insufficiency treated by foam sclerosant. Ann Vasc Surg 2006; 20: 83-91
• 17 Stücker M, Reich S, Hermes N et al. Sicherheit und Effektivität der periulzerösen Schausmsklerosierung bei Patienten mit postthrombotischem Syndrom und/oder oraler Antikoagulation mit Phenprocoumon. JDDG 2006; 9: 734-738
• 18 Lee BB et al. Congenital vascular malformations: general treatment principles. Phlebology 2007; 22: 258-263
• 19 Rabe E, Pannier F. Sclerotherapy in venous malformation. Phlebology 2013; 28 (Suppl. 01) 188-191
• 20 Blaise S, Charavin-Cocuzza M, Riom H et al. Treatment of low-flow vascular malformations by ultrasound guided sclerotherapy with polidocanol foam: 24 cases and literature review. Eur J Endovasc Surg 2011; 41: 412-417
• 21 Recke AL, Devereux N, Kahle B. Steigerung der Lebensqualität nach Schaumsklerosierung einer multipel voroperierten vaskulären Malformation. Phlebologie 2013; 42: 77-80
• 22 Klode J, Klötgen K, Körber A et al. Polidocanol foam sclerotherapy is a new and effektive treatment for post-operative lymphorrhoe and lymphocele. J Eur Acad Dermatol Venereol 2010; 24: 904-909
• 23 Moritz RK, Reich-Schupke S, Altmeyer P et al. Polidocanol foam sclerotherapy of persisting postoperative seromas after varicose vein surgery: a series of six cases. Phlebology 2013; 28: 341-346
• 24 Kahle B, Denk K, Schliephake D et al. Effektivität der Sklerosierungstherapie in Abhängigkeit vom Alter. Phlebologie 2010; 39: 202-207
• 25 Huncu H. Sclerotherapy: a study comparing polidocanol in foam and liquid form. Phlebology 2010; 25: 44-49